Halozyme Therapeutics, Inc. (HALO) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en San Diego, CA, United States. El CEO actual es Helen I. Torley.
HALO tiene fecha de IPO 2004-03-16, 350 empleados a tiempo completo, cotiza en el NASDAQ Global Select, una capitalización de mercado de $7.97B.
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company headquartered in San Diego, California, with operations across the United States, Switzerland, Ireland, Belgium, Japan, and other international markets. The company's core proprietary technology, ENHANZE, is based on a recombinant human hyaluronidase enzyme (rHuPH20) that enables subcutaneous delivery of injectable biologics, including monoclonal antibodies and other therapeutic molecules. Halozyme develops and commercializes multiple products across oncology, immunology, and rare disease areas, including Hylenex, RITUXAN HYCELA, HYQVIA, and collaborates with leading pharmaceutical companies such as Roche, Pfizer, AbbVie, and Bristol-Myers Squibb on various therapeutic programs targeting cancer, autoimmune diseases, and infectious diseases. Founded in 1998, the company leverages its advanced drug delivery platform to enhance the efficacy and patient convenience of treatments across multiple therapeutic areas.
